30
Participants
Start Date
March 8, 2019
Primary Completion Date
September 30, 2021
Study Completion Date
December 30, 2025
Nivolumab
Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
Ipilimumab
Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
University of Pittsburgh Medical Center, Pittsburgh
University of Texas Southwestern Medical Center, Dallas
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Dana-Farber Cancer Institute
OTHER